What are the best predictors for successful GnRH antagonist protocol in in vitro fertilization (IVF) treatment?

Abstract Objective: To determine factors that affect the success rate of GnRH antagonist protocol in in vitro fertilization (IVF) treatment. Design: Retrospective cohort study. Patients: Patients who underwent IVF cycle with their first GnRH antagonist protocol. Intervention: Antagonist protocol during IVF treatment. The main outcome measurements were; Number of retrieved oocytes, embryo quality and pregnancy rate. Results: Gravidity was negatively correlated with number of eggs (p = 0.017), while total follicle number ≥15 (p = 0.044) and E2 on day of human chorionic gonadotropin (HCG) (p = 0.000) had a positive correlation with number of eggs. Maximum follicle size at HCG administration showed a trend toward an inverse correlation (p = 0.053). Addition of LH to drug stimulation was negatively correlated with number of eggs in comparison to rFSH only (p = 0.013 and 0.0000, respectively). Age and number of frozen eggs were negatively correlated with successful pregnancy (p = 0.025 and 0.004, respectively), while embryo quality, gravidity and number of embryos were positive (p = 0.011 and 0.014, respectively). Conclusion: Controlled parameters like timing of antagonist start, duration of antagonist and the optimal leading follicle diameter for HCG triggering had no effect on treatment outcomes. Chinese abstract 目的:确定在体外受精(IVF)治疗中影响GnRH拮抗剂方案成功的因素。设计:回顾性队列研究。患者:进行IVF周期,第一次应用GnRH拮抗剂方案的患者。干预:IVF中应用拮抗剂方案。主要测定结果:取卵数、胚胎质量和妊娠率。 结果:妊娠与卵子数呈负相关(p = 0.017),然而当总卵泡数≥15个 (p = 0.044) ,注射人绒毛膜促性腺激素(HCG)日的E2 (p = 0.000)与卵子数呈正相关,与注射HCG日最大卵泡大小呈负相关趋势(p =0.053)。药物刺激中添加的LH与卵泡数呈负相关,与rFSH比较只有(分别为p=0.013 、 P=0.0000)年龄和冷冻卵子数与成功妊娠呈负相关(分别为p=0.025 ,p=0.004),然而胚胎质量,妊娠和胚胎数呈正相关。(p =0.011,p=0.014). 结论:控制的参数如拮抗剂开始的时间,拮抗剂应用的时间和最优的主导卵泡的直径对HCG诱导排卵治疗结局没有影响。

[1]  Julie Brown,et al.  Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. , 2016, The Cochrane database of systematic reviews.

[2]  M. Mainigi,et al.  Why we should transfer frozen instead of fresh embryos: the translational rationale. , 2014, Fertility and sterility.

[3]  H. Qi,et al.  Timing of human chorionic gonadotropin (hCG) hormone administration in IVF/ICSI protocols using GnRH agonist or antagonists: a systematic review and meta-analysis , 2014, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[4]  P. Patrizio,et al.  Fresh transfer outcome predicts the success of a subsequent frozen transfer utilizing blastocysts of the same cohort. , 2014, Reproductive biomedicine online.

[5]  M. Boaz,et al.  The effect of delayed initiation of gonadotropin-releasing hormone antagonist in a flexible protocol on in vitro fertilization outcome. , 2013, Fertility and sterility.

[6]  A. Balen,et al.  Timing of human chorionic gonadotrophin (hCG) hormone administration in IVF protocols using GnRH antagonists: a randomized controlled trial , 2012, Human fertility.

[7]  G. Garruti,et al.  GnRH agonist versus GnRH antagonist in in vitro fertilization and embryo transfer (IVF/ET) , 2012, Reproductive Biology and Endocrinology.

[8]  H. Tournaye,et al.  Is earlier administration of human chorionic gonadotropin (hCG) associated with the probability of pregnancy in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone (GnRH) antagonists? A prospective randomized trial. , 2011, Fertility and sterility.

[9]  C. Simón,et al.  Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis. , 2011, Fertility and sterility.

[10]  M. Lane,et al.  Avoidance of weekend oocyte retrievals during GnRH antagonist treatment by simple advancement or delay of hCG administration does not adversely affect IVF live birth outcomes. , 2010, Human reproduction.

[11]  E. Puscheck,et al.  Timing and duration of use of GnRH antagonist down-regulation for IVF/ICSI cycles have no impact on oocyte quality or pregnancy outcomes , 2008, Journal of Assisted Reproduction and Genetics.

[12]  E. Kolibianakis,et al.  Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? A systematic review and meta-analysis. , 2007, Human reproduction update.

[13]  H. Tournaye,et al.  Administration of gonadotropin-releasing hormone antagonist from day 1 of stimulation in in vitro fertilization. , 2004, Fertility and sterility.

[14]  E. Hernández,et al.  Embryo implantation and GnRH antagonists: embryo implantation: the Rubicon for GnRH antagonists. , 2000, Human reproduction.

[15]  R. Hermann,et al.  Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist Cetrorelix in healthy female volunteers. , 1998, Human reproduction.

[16]  Matheus Roque,et al.  Fresh embryo transfer versus frozen embryo transfer in in vitro fertilization cycles: a systematic review and meta-analysis. , 2013, Fertility and sterility.

[17]  M. Mann,et al.  Dual effects of superovulation: loss of maternal and paternal imprinted methylation in a dose-dependent manner. , 2010, Human molecular genetics.

[18]  H. Al-Inany Clinical consequences of ovarian stimulation in assisted conception and in PCOS , 2006 .